Teva Pharmaceutical Industries Limited (TEVJF)
Market Cap | 18.69B |
Revenue (ttm) | 16.63B |
Net Income (ttm) | -157.00M |
Shares Out | n/a |
EPS (ttm) | -0.14 |
PE Ratio | n/a |
Forward PE | 6.29 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 904 |
Average Volume | 504 |
Open | 14.00 |
Previous Close | 17.80 |
Day's Range | 14.00 - 14.00 |
52-Week Range | 13.73 - 22.91 |
Beta | 0.62 |
RSI | 43.31 |
Earnings Date | Jul 30, 2025 |
About Accolade
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
Full Company ProfileFinancial Performance
In 2024, TEVJF's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.
Financial StatementsNews
Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The Upside
Teva CEO: Our supply chain puts us in a strong position
Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent earnings report.

Teva CEO: Our supply chain puts us in a strong position
Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent earnings report.
Teva Pharmaceutical Industries Limited (TEVA) Q2 2025 Earnings Call Transcript
Teva posts Q2 revenue miss as generic products underperform
Why Drugmaker Teva Pharmaceutical Narrowed Full-Year Guidance After Beating Q2 Earnings
Teva stock is trading below key levels.

Teva Pharm Q2 profit beats estimates as branded drugs gain
Teva Pharmaceutical Industries reported a higher than expected rise in second-quarter profit, helped by strong sales gains of its branded drugs to treat migraines, Huntington's disease and schizophren...
Teva Pharmaceutical Non-GAAP EPS of $0.66 beats by $0.04, revenue of $4.18B misses by $90M

Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will release its second-quarter 2025 financial results tomorrow, July 30 . According to Benzinga Pro , the company expects to report second-quarter ea...

Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong
Teva Pharmaceutical Industries Ltd. TEVA will release its second-quarter 2025 financial results tomorrow, July 30.

A Glimpse of Teva Pharmaceutical Indus's Earnings Potential
Teva Pharmaceutical Indus (NYSE: TEVA) is set to give its latest quarterly earnings report on Wednesday, 2025-07-30. Here's what investors need to know before the announcement. Analysts estimate that...
Teva Pharmaceutical Q2 2025 Earnings Preview

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review
As the pharmaceutical industry increasingly focuses on developing targeted treatments for niche conditions, Viatris Inc . (NASDAQ: VTRS) on Friday announced topline data from a Phase 3 study evaluati...
Looking Into Teva Pharmaceutical Indus's Recent Short Interest
Teva Pharmaceutical Indus's (NYSE: TEVA) short percent of float has risen 11.82% since its last report. The company recently reported that it has 40.00 million shares sold short , which is 3.5% of al...
J&J wins appeals court ruling against Teva and Viatris in patent dispute over neuro drug
Teva Pharmaceutical Industries Ltd (TEVA) Recognized Among World's Most Sustainable Companies | ...
Teva Pharmaceutical Industries Ltd (TEVA) Recognized Among World's Most Sustainable Companies | TEVA stock news

Teva Releases Q2 2025 Aide Memoire
TEL AVIV, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2025 Aide Memoire is available on the “Investors” page on its ...

Viatris Eye Drops Data Shows Promise For Blurred Near Vision
Viatris Inc. (NASDAQ: VTRS) and Opus Genetics, Inc. (NASDAQ: IRD) revealed topline results from VEGA-3, the second pivotal Phase 3 trial evaluating MR-141 (phentolamine ophthalmic solution 0.75%) fo...
Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility
REYKJAVIK, ICELAND (June 26, 2025) — Alvotech (NASDAQ: ALVO , ALVO SDB, the "Company")), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients w...

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025
TEL AVIV, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2025 financial re...

Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine
TEL AVIV, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the final analysis of the pan-European PEARL Phase 4 migraine prevent...
Teva and Fosun partner to develop TEV-56278 against cancers

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun Pharma-Teva collaboration agreement established with ...